Innovent Biologics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 6,206.07 million compared to CNY 4,556.38 million a year ago. Net loss was CNY 1,027.91 million compared to CNY 2,179.27 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.15 HKD | +1.56% | +17.92% | -8.42% |
Apr. 17 | Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer | CI |
Apr. 02 | Hutchmed endometrial cancer treatment application accepted for review | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.42% | 8.12B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 1801 Stock
- News Innovent Biologics, Inc.
- Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023